When does Aspen expect approval for its generic GLP-1 in Canada?

Aspen expects Canadian regulatory approval for its generic GLP-1 obesity treatment between May and September 2026.

What is Aspen's outlook on the GLP-1 market?

Aspen anticipates GLP-1s to remain a durable long-term growth driver, expecting significant volumes despite anticipated price competition.

Where does Aspen see the greatest potential for its generic GLP-1s?

Aspen sees significant potential in emerging markets, where lower price points could unlock demand for patients unable to afford branded products.

Home / Business and Economy / Aspen Pharma Eyes Early GLP-1 Generic Entry in Canada

Aspen Pharma Eyes Early GLP-1 Generic Entry in Canada

4 Mar

•

Summary

Aspen expects Canadian approval for its generic GLP-1 by September.
Company aims to be among the first to market its semaglutide copycat.
Emerging markets offer significant potential for lower-priced generics.

Aspen Pharma Eyes Early GLP-1 Generic Entry in Canada

Aspen Pharmacare is poised to enter the Canadian market with its generic GLP-1 obesity treatment, aiming for regulatory approval between May and September of 2026. This strategic move seeks to establish an early presence in a significant market following the patent expiry of Novo Nordisk's Ozempic.

CEO Stephen Saad expressed confidence that Aspen's semaglutide copycat could achieve swift uptake in Canada, potentially serving as a benchmark for launches in Latin American and Middle Eastern countries. While acknowledging the increased competition expected in the generics market, Saad anticipates substantial volumes and profitability.

The company also foresees greater opportunities in emerging markets, where a more accessible price point for generic GLP-1s could unlock demand for a vast population unable to afford branded medications.

Aspen has invested heavily in GLP-1 manufacturing and debt reduction. The company reported a 4.1% decrease in first-half revenue to 21.1 billion rand. Shares saw a 0.5% increase, contributing to a 16% gain this year.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.